Artificial Intelligence Tool Estimates Cancer Patients' Survival Chances Using Facial Features

Researchers in the US have developed an artificial intelligence (AI) tool that uses facial features to estimate how ill patients are and their chances of survival from cancer. The "FaceSurvival" AI tool was trained on a vast dataset comprising millions of healthy faces and 35,000 photographs of cancer patients.

The tool zeroes in on specific areas around the eyes and nose when making its estimates. According to the researchers, these features hold crucial information that can help doctors gauge the severity of a patient's condition and make informed treatment recommendations. The AI tool is not intended to replace human medical professionals but rather serve as an auxiliary diagnostic aid.

The dataset used to train FaceSurvival includes patients with various types of cancer at different stages of progression, including cases where the disease had spread to bones or the brain. The age range of the cancer patients varies significantly, spanning from children to individuals in their 90s.

The preliminary findings of this research have been published in a leading digital health journal. While the tool is still in its experimental phase and not yet ready for clinical use, it has sparked interest among medical professionals who see potential benefits in using AI to support patient diagnosis.

Further refinement of the FaceSurvival tool is required before it can be integrated into hospital settings. Nevertheless, researchers are optimistic about its prospects as a supplementary diagnostic aid that could help doctors make more informed decisions about treatment options for their patients.

As people age, doctors are increasingly seeking ways to estimate their physical reserve and frailty before recommending intensive treatments. This is where a novel approach comes into play - using a simple photo of a person's face as a diagnostic aid.

The idea may seem unorthodox, but researchers believe that facial features can provide valuable insights into an individual's health status. For instance, certain characteristics such as wrinkles and folds on the skin can be indicative of physical decline. By analyzing these visual cues, doctors may be able to make more informed decisions about treatment options for their patients.

One tool being evaluated in this context is called 'FaceAge', which uses artificial intelligence to predict biological age - a measure that takes into account how old someone looks compared to their actual age. The tool focuses on specific areas of the face, including the nasolabial folds and marionette lines around the mouth, as well as the forehead, temples, and cheeks.

These facial features are thought to be indicative of overall health, with certain lifestyle habits potentially accelerating the aging process. For example, heavy alcohol use, drug abuse, and smoking can all take a toll on physical appearance. Researchers have found that the 'FaceAge' tool is surprisingly consistent across various photos, despite differences in pose, lighting, facial expression, and makeup.

The findings suggest that this approach could provide valuable supplementary information for doctors to consider when making treatment decisions. By combining visual cues with other diagnostic methods, healthcare professionals may be able to gain a more comprehensive understanding of an individual's health status.

The research on using facial photos to estimate biological age has shown promising results in various medical procedures, including plastic surgery, with some minor exceptions.

However, the researchers emphasize that their findings are based on limited data and more extensive testing is required to determine the accuracy of these tools across different ethnic groups.

To advance this technology, the research team is seeking public participation by uploading facial photos for analysis, which will provide a personalized biological age estimate.

Experts caution that while this tool demonstrates potential, it is still in its developmental stages and not yet ready for clinical use, requiring further testing against medical professionals' judgments.